Transmission pathways and mediators as the basis for clinical pharmacology of pain

References

• Hartvigsen J, Davidsen M, Sogaard K, et al. Self-reported musculoskeletal pain predicts long-term increase in general health care use: a population-based cohort study with 20-year follow-up. Scand J Public Health. 2014;42(7):698–704.
   PubMed Web of Science ®Google Scholar
• Ford A, Castonguay A, Cottet M, et al. Engagement of the GABA to KCC2 signaling pathway contributes to the analgesic effects of A3AR agonists in neuropathic pain. J Neurosci. 2015 15;35(15):6057–6067.
   PubMed Web of Science ®Google Scholar
• Chen J-F, Eltzschig HK, Fredholm BB. Adenosine receptors as drug targets – what are the challenges? Nat Rev Drug Discov. 2013;12(4):265–286.
   PubMed Web of Science ®Google Scholar
• Imlach W, Bhola R, May L, et al. A positive allosteric modulator of the adenosine A1 receptor selectively inhibits primary afferent synaptic transmission in a neuropathic pain model. Mol Pharmacol. 2015;88(3):460.
   PubMed Web of Science ®Google Scholar
• Otsuguro K, Tomonari Y, Otsuka S, et al. An adenosine kinase inhibitor, ABT-702, inhibits spinal nociceptive transmission by adenosine release via equilibrative nucleoside transporters in rat. Neuropharmacology. 2015;97:160–170.
   PubMed Web of Science ®Google Scholar
• Yang J-N, Bjorklund O, Lindstrom-Tornqvist K, et al. Mice heterozygous for both A1 and A2A adenosine receptor genes show similarities to mice given long-term caffeine. J Appl Physiol. 2008;106(2):631–639.
   PubMed Web of Science ®Google Scholar
• Derry CJ, Derry S, Moore RA. Caffeine as an analgesic adjuvant for acute pain in adults. Cochrane Database Syst Rev. 2014. doi:10.1002/14651858.CD009281.pub3.
   Web of Science ®Google Scholar
• Little JW, Ford A, Symons-Liguori AM, et al. Endogenous adenosine A3 receptor activation selectively alleviates persistent pain states. Brain. 2015;138(Pt 1):28–35.
   PubMed Web of Science ®Google Scholar
• Janes K, Esposito E, Doyle T, et al. A3 adenosine receptor agonist prevents the development of paclitaxel-induced neuropathic pain by modulating spinal glial-restricted redox-dependent signaling pathways. Pain. 2014;155(12):2560–2567.
   PubMed Web of Science ®Google Scholar
• Ford A, Castonguay A, Cottet M, et al. Engagement of the GABA to KCC2 signaling pathway contributes to the analgesic effects of A3AR agonists in neuropathic pain. J Neurosci. 2015;35(15):6057–6067.
   PubMed Web of Science ®Google Scholar
• Huang H, Player M. Bradykinin B1 receptor antagonists as potential therapeutic agents for pain. J Med Chem. 2010;53:5383–5399.
   PubMed Web of Science ®Google Scholar
• Gardes J, Michineau S, Pizard A, et al. Aspirin inhibits human bradykinin B2 receptor ligand binding function. Biochem Pharmacol. 2008;75(9):1807–1816.
   PubMed Web of Science ®Google Scholar
• Kennedy WR, Vanhove GF, Lu S-P, et al. A randomized, controlled, open-label study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers. J Pain. 2010;11(6):579–587.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhang M, Sun G, et al. Calcitonin gene-related peptide promotes the wound healing of human bronchial epithelial cells via PKC and MAPK pathways. Regul Pept. 2013;184:22–29. doi:10.1016/j.regpep.2013.03.020.
   PubMedGoogle Scholar
• Hansen JM, Hauge AW, Olesen J, et al. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia. 2010;30(10):1179–1186.
   PubMed Web of Science ®Google Scholar
• Romero-Reyes M, Pardi V, Akerman S. A potent and selective calcitonin gene-related peptide (CGRP) receptor antagonist, MK-8825, inhibits responses to nociceptive trigeminal activation: role of CGRP in orofacial pain. Exp Neurol. 2015;271:95–103. doi:10.1016/j.expneurol.2015.05.005.
   PubMed Web of Science ®Google Scholar
• Hansen JM, Hauge AW, Olesen J, et al. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia. 2010;30(10):1179–1186.
   PubMed Web of Science ®Google Scholar
• Marcus R, Goadsby P, Dodick D, et al. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014;34(2):114–125.
   PubMed Web of Science ®Google Scholar
• Greco R, Mangione A, Siani F, et al. Effects of CGRP receptor antagonism in nitroglycerin-induced hyperalgesia. Cephalalgia. 2014;34(8):594–604.
   PubMed Web of Science ®Google Scholar
• Ho TW, Ho AP, Ge YJ, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine. Cephalgia. 2016;36(2):148–161.
   Web of Science ®Google Scholar
• Altun A, Yildirim K, Ozdemir E, et al. Attenuation of morphine anti-nociceptive tolerance by cannabinoid CB1 and CB2 receptor antagonists. J Physiol Sci. 2015;65:407–415.
   PubMed Web of Science ®Google Scholar
• Peciña M, Martínez-Jauand M, Hodgkinson C, et al. FAAH selectively influences placebo effects. Molecular Psychiatry. 2014;19(3):385–391.
   PubMed Web of Science ®Google Scholar
• Pawsey S, Wood M, Browne H, et al. Safety, tolerability and pharmacokinetics of FAAH inhibitor V158866: a double-blind, randomised, placebo-controlled phase I study in healthy volunteers. Drugs R D. 2016;16(2):181–191.
   PubMedGoogle Scholar
• Cooper ZD, Comer SD, Haney M. Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers. Neuropsychopharmacology. 2013;38(10):1984–1992.
   PubMed Web of Science ®Google Scholar
• Darmani NA, Izzo AA, Degenhardt B, et al. Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies. Neuropharmacology. 2005;48(8):1154–1163.
   PubMed Web of Science ®Google Scholar
• Ostenfeld T, Price J, Albanese M, et al. A randomized, controlled study to investigate the analgesic efficacy of single doses of the cannabinoid receptor-2 agonist GW842166, ibuprofen or placebo in patients with acute pain following third molar tooth extraction. Clin J Pain. 2011;27(8):668–676.
   PubMed Web of Science ®Google Scholar
• Wilsey B, Marcotte T, Deutsch R, et al. Low-dose vaporized cannabis significantly improves neuropathic pain. J Pain. 2013;14(2):136–148.
   PubMed Web of Science ®Google Scholar
• Johnson JR, Lossignol D, Burnell-Nugent M, et al. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manage. 2013;46(2):207–218.
   PubMed Web of Science ®Google Scholar
• Alkaitis MS, Solorzano C, Landry RP, et al. Evidence for a role of endocannabinoids, astrocytes and p38 phosphorylation in the resolution of postoperative pain. PLoS One. 2010;5:e10891.
   PubMed Web of Science ®Google Scholar
• Landry RP, Martinez E, DeLeo JA, et al. Spinal cannabinoid receptor type 2 agonist reduces mechanical allodynia and induces mitogen-activated protein kinase phosphatases in a rat model of neuropathic pain. J Pain. 2012;13(9):836–848.
   PubMed Web of Science ®Google Scholar
• Paszcuk AF, Dutra RC, da Silva KABS, et al. Cannabinoid agonists inhibit neuropathic pain induced by brachial plexus avulsion in mice by affecting glial cells and MAP kinases. PLoS ONE. 2011;6(9):e24034.
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015 28;14(2):162–173.
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Ganae-Motan ED, Allende S, et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. 2012;13(5):438–449.
   PubMed Web of Science ®Google Scholar
• Hammond V, O’Donnell V. Esterified eicosanoids: generation, characterization and function. Biochim Biophys Acta. 2012;1818(10):2403–2412.
   PubMed Web of Science ®Google Scholar
• Inceoglu B, Jinks SL, Ulu A, et al. Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways. Proc Natl Acad Sci USA. 2008;105:18901–18906.
   PubMed Web of Science ®Google Scholar
• Hennan JK, Huang J, Barrett TD, et al. Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Basic Sci Rep. 2001;104:820–825. doi:10.1161/hc3301.092790.
   Web of Science ®Google Scholar
• St-Jacquesa B, Ma W. Peripheral prostaglandin E2 prolongs the sensitization of nociceptive dorsal root ganglion neurons possibly by facilitating the synthesis and anterograde axonal trafficking of EP4 receptors. Exp Neurol. 2014;261:354–366.
   PubMed Web of Science ®Google Scholar
• Hong TT, Huang J, Barrett TD, et al. Effects of cyclooxygenase inhibition on canine coronary artery blood flow and thrombosis. Am J Physiol Heart Circ Physiol. 2008;294(1):H145–H155. doi:10.1152/ajpheart.00646.2007.
   Google Scholar
• Liua B, Luob W, Zhanga Y, et al. Effect of celecoxib on cyclooxygenase-1-mediated prostacyclin synthesis and endothelium-dependent contraction in mouse arteries. Euro J Pharmacol. 2013;698(1–3):354–361.
   PubMed Web of Science ®Google Scholar
• Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769–779. doi:10.1016/S0140-6736(13)60900-9.
   PubMed Web of Science ®Google Scholar
• Mizoguchi H, Takagi H, Watanabe C, et al. Involvement of multiple µ-opioid receptor subtypes on the presynaptic or postsynaptic inhibition of spinal pain transmission. Peptides. 2014;51:15–25.
   PubMed Web of Science ®Google Scholar
• Richards P, Gimbel JS, Minkowitz HS, et al. Comparison of the efficacy and safety of dual-opioid treatment with morphine plus oxycodone versus oxycodone/acetaminophen for moderate to severe acute pain after total knee arthroplasty. Clin Ther. 2013;35(4):498–511.
   PubMed Web of Science ®Google Scholar
• Richards P, Riff D, Kelen R, et al. Analgesic and adverse effects of a fixed-ratio morphine-oxycodone combination (MoxDuo®) in the treatment of postoperative pain. J Opioid Manage. 2011;7(3):217–228.
   PubMedGoogle Scholar
• Imanaka K, Tominaga Y, Etropolski M, et al. Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release. Clin Drug Investig. 2014;34(7):501–511.
   PubMed Web of Science ®Google Scholar
• Lu Z, Xu J, Rossi GC, et al. Mediation of opioid analgesia by a truncated 6-transmembrane GPCR. J Clin Invest. 2015;125(7):2626.
   PubMed Web of Science ®Google Scholar
• Pang W, Liu Y-C, Maboudou E, et al. Metoclopramide improves the quality of tramadol PCA indistinguishable to morphine PCA: a prospective, randomized, double blind clinical comparison. Pain Med. 2013;14(9):1426–1434.
   PubMedGoogle Scholar
• Lin S-L, Tsai R-Y, Shen C-H, et al. Co-administration of ultra-low dose naloxone attenuates morphine tolerance in rats via attenuation of NMDA receptor neurotransmission and suppression of neuroinflammation in the spinal cords. Pharmacol Biochem Behav. 2010;96(2):236–245.
   PubMed Web of Science ®Google Scholar
• Tsai R-Y, Cheng Y-C, Wong C-S. (+)-Naloxone inhibits morphine-induced chemotaxis via prevention of heat shock protein 90 cleavage in microglia. J Formos Med Assoc. 2015;114(5):446–455.
   PubMed Web of Science ®Google Scholar
• Lin Y-S, Tsai R-Y, Shen C-H, et al. Ultra-low dose naloxone restores the antinocicepitve effect of morphine in PTX-treated rats: association of IL-10 upregulation in the spinal cord. Life Sci. 2012;91(5–6):213–220.
   PubMed Web of Science ®Google Scholar
• Jordan BA, Devi LA. G-protein-coupled receptor heterodimerization modulates receptor function. Nature. 1999;399(6737):697–700.
   PubMed Web of Science ®Google Scholar
• Wang H-L, Hsu C-Y, Huang P-C, et al. Heterodimerization of opioid receptor-like 1 and mu-opioid receptors impairs the potency of micro receptor agonist. J Neurochem. 2005;92(6):1285–1294.
   PubMed Web of Science ®Google Scholar
• Pfeiffer M, Kirscht S, Stumm R, et al. Heterodimerization of substance P and μ-opioid receptors regulates receptor trafficking and resensitization. J Biol Chem. 2003;278(51):51630–51637.
   PubMed Web of Science ®Google Scholar
• Guillemyn K, Starnowska J, Lagard C, et al. Bifunctional peptide-based opioid agonist–nociceptin antagonist ligands for dual treatment of acute and neuropathic pain. J Med Chem. 2016;59(8):3777–3792.
   PubMed Web of Science ®Google Scholar
• Doehring A, Oertel BG, Sittl R, et al. Chronic opioid use is associated with increased DNA methylation correlating with increased clinical pain. Pain. 2013;154(1):15–23.
   PubMed Web of Science ®Google Scholar
• Chao Y-C, Xie F, Li X, et al. Demethylation regulation of BDNF gene expression in dorsal root ganglion neurons is implicated in opioid-induced pain hypersensitivity in rats. Neurochem Int. 2016;97:91–98. doi:10.1016/j.neuint.2016.03.007.
   PubMed Web of Science ®Google Scholar
• Lee C-Y, Perez FM, Wang W, et al. Dynamic temporal and spatial regulation of mu opioid receptor expression in primary afferent neurons following spinal nerve injury. Eur J Pain. 2011;15(7):669–675.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen S-R, Laumet G, et al. Nerve injury diminishes opioid analgesia through lysine methyltransferase-mediated transcriptional repression of μ-opioid receptors in primary sensory neurons. J Biol Chem. 2016;291:8475–8485.
   PubMed Web of Science ®Google Scholar
• Grace PM, Strand KA, Galer EL, et al. Morphine paradoxically prolongs neuropathic pain in rats by amplifying spinal NLRP3 inflammasome activation. Proc Natl Acad Sci. 2016;113(24):E3441–E3450.
   PubMed Web of Science ®Google Scholar
• Munro G, Hansen R, Mirza N. GABA(A) receptor modulation: potential to deliver novel pain medicines? Eur J Pharmacol. 2013;716(1–3):17–23.
   PubMed Web of Science ®Google Scholar
• Munro G, Erichsen HK, Rae MG, et al. A question of balance--positive versus negative allosteric modulation of GABA(A) receptor subtypes as a driver of analgesic efficacy in rat models of inflammatory and neuropathic pain. Neuropharmacology. 2011;61(1–2):121–132.
   PubMed Web of Science ®Google Scholar
• Mirza NR, Larsen JS, Mathiasen C, et al. NS11394 [3′-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile], a unique subtype-selective GABAA receptor positive allosteric modulator: in vitro actions, pharmacokinetic properties and in vivo anxiolytic efficacy. J Pharmacol Exp Ther. 2008;327(3):954–968.
   PubMed Web of Science ®Google Scholar
• Munro G, Lopez-Garcia JA, Rivera-Arconada I, et al. Comparison of the novel subtype-selective GABAA receptor-positive allosteric modulator NS11394 [3′-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile] with diazepam, zolpidem, bretazenil, and gaboxadol in rat models of inflammatory and neuropathic pain. J Pharmacol Exp Ther. 2008;327(3):969–981.
   PubMed Web of Science ®Google Scholar
• Hu J-H, Yang N, Ma Y-H, et al. Hyperalgesic effects of gamma-aminobutyric acid transporter I in mice. J Neurosci Res. 2003;73:565–572.
   PubMed Web of Science ®Google Scholar
• Xu YF, Cai YQ, Cai GQ, et al. Hypoalgesia in mice lacking GABA transporter subtype 1. J Neurosci Res. 2008;86:465–470.
   PubMed Web of Science ®Google Scholar
• Todorov AA, Kolchev CB, Todorov AB. Tiagabine and gabapentin for the management of chronic pain. Clin J Pain. 2005;21(4):358–361.
   PubMed Web of Science ®Google Scholar
• Kataoka K, Hara K, Haranishi Y, et al. The anti-nociceptive effect of SNAP5114, a gamma-aminobutyric acid transporter-3 inhibitor, in rat experimental pain models. Anesth Analg. 2013;116(5):1162–1169.
   PubMed Web of Science ®Google Scholar
• Ford A, Castonguay A, Cottet M, et al. Engagement of the GABA to KCC2 signaling pathway contributes to the analgesic effects of A3AR agonists in neuropathic pain. J Neurosci. 2015;35(15):6057–6067.
   PubMed Web of Science ®Google Scholar
• Valencia-de Ita S, Lawand NB, Lin Q, et al. Role of the Na+-K+-2Cl- cotransporter in the development of capsaicin-induced neurogenic inflammation. J Neurophysiol. 2006;95(6):3553–3561.
   PubMed Web of Science ®Google Scholar
• Gagnon M, Bergeron MJ, Lavertu G, et al. Chloride extrusion enhancers as novel therapeutics for neurological diseases. Nat Med. 2013;19(11):1524–1528.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Cai Y-Q, Zou F, et al. Epigenetic suppression of GAD65 expression mediates persistent pain. Nat Med. 2011;17:1448–1455.
   PubMed Web of Science ®Google Scholar
• Tao W, Chen Q, Wang L, et al. Brainstem brain-derived neurotrophic factor signaling is required for histone deacetylase inhibitor-induced pain relief. Mol Pharmacol. 2015;87(6):1035–1041.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Tao W, Hou -Y-Y, et al. Persistent pain facilitates response to morphine reward by downregulation of central amygdala GABAergic function. Neuropsychopharmacol. 2014;39(9):2263–2271.
   PubMed Web of Science ®Google Scholar
• Yuan W-X, Chen S-R, Chen H, et al. Stimulation of α1-adrenoceptors reduces glutamatergic synaptic input from primary afferents through GABAA receptors and T-type Ca2+ channels. Neurosci. 2009;158(4):1616–1624.
   PubMed Web of Science ®Google Scholar
• Tao Y-X. Dorsal horn alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor trafficking in inflammatory pain. Anesthesiology. 2010;112(5):1259–1265.
   PubMed Web of Science ®Google Scholar
• Li Y, Wang H, Xie K, et al. Inhibition of glycogen synthase kinase-3β prevents remifentanil-induced hyperalgesia via regulating the expression and function of spinal N-methyl-D-aspartate receptors in vivo and in vitro. PLoS One. 2013;8(10):e77790.
   PubMed Web of Science ®Google Scholar
• Bonnet CS, Williams AS, Gilber SJ, et al. AMPA/kainate glutamate receptors contribute to inflammation, degeneration and pain related behaviour in inflammatory stages of arthritis. Ann Rheum Dis. 2015;74:242–251.
   PubMed Web of Science ®Google Scholar
• Wang X-T, Lian X, Xu Y-M, et al. α(2) noradrenergic receptor suppressed CaMKII signaling in spinal dorsal horn of mice with inflammatory pain. Eur J Pharmacol. 2014;724:16–23.
   PubMed Web of Science ®Google Scholar
• Wang K, Svensson P, Sessle BJ, et al. Interactions of glutamate and capsaicin-evoked muscle pain on jaw motor functions of men. Clin Neurophysiol. 2010;121(6):950–956.
   PubMed Web of Science ®Google Scholar
• Baad-Hansen L, Cairns BE, Ernberg M, et al. Effect of systemic monosodium glutamate (MSG) on headache and pericranial muscle sensitivity. Cephalgia. 2010;30(1):68–76.
   PubMed Web of Science ®Google Scholar
• Truini A, Piroso S, Pasquale E, et al. N-acetyl-cysteine, a drug that enhances the endogenous activation of group-II metabotropic glutamate receptors, inhibits nociceptive transmission in humans. Mol Pain. 2015;11:14.
   PubMed Web of Science ®Google Scholar
• Nam M, Kim TH, Kwak J, et al. Discovery and biological evaluation of tetrahydrothieno[2,3-c]pyridine derivatives as selective metabotropic glutamate receptor 1 antagonists for the potential treatment of neuropathic pain. Eur J Med Chem. 2015;97:245–258.
   PubMed Web of Science ®Google Scholar
• Castel A, Helie P, Beaudry F, et al. Bilateral central pain sensitization in rats following a unilateral thalamic lesion may be treated with high doses of ketamine. BMC Vet Res. 2013;9:59.
   PubMed Web of Science ®Google Scholar
• Shrestha R, Pant S, Shrestha A, et al. Intranasal ketamine for the treatment of patients with acute pain in the emergency department. World J Emerg Med. 2016;7(1):19–24.
   PubMed Web of Science ®Google Scholar
• Laskowski K, Stirling A, McKay WP, et al. A systematic review of intravenous ketamine for postoperative analgesia. Can J Anesth. 2011;58(10):911–923.
   PubMed Web of Science ®Google Scholar
• Hu Y-M, Chen S-R, Chen H, et al. Casein kinase II inhibition reverses pain hypersensitivity and potentiated spinal N-methyl-D-aspartate receptor activity caused by calcineurin inhibitor. J Pharmacol Exp Ther. 2014;349(2):239–247.
   PubMed Web of Science ®Google Scholar
• Tong W, Maira M, Gagnon M, et al. Ligands binding to cell surface ganglioside GD2 cause src-dependent activation of N-methyl-daspartate receptor signaling and changes in cellular morphology. PLoS One. 2015;10(8):e0134255.
   Google Scholar
• Murphy JD, Paskaradevan JA, Eisler LL, et al. Analgesic efficacy of continuous intravenous magnesium infusion as an adjuvant to morphine for postoperative analgesia: a systematic review and meta-analysis. Middle East J Anesthesiol. 2013;22(1):11–20.
   PubMedGoogle Scholar
• Ko M-H, Hsieh Y-L, Hsieh S-T, et al. Nerve demyelination increases metabotropic glutamate receptor subtype 5 expression in peripheral painful mononeuropathy. Int J Mol Sci. 2015;16(3):4642–4665.
   PubMed Web of Science ®Google Scholar
• Qiu S, Zhang M, Liu Y, et al. GluA1 phosphorylation contributes to postsynaptic amplification of neuropathic pain in the insular cortex. J Neurosci. 2014;34(40):13505–13515.
   PubMed Web of Science ®Google Scholar
• Chen S-R, Zhou H-Y, Byun HS, et al. Nerve injury increases GluA2-lacking AMPA receptor prevalence in spinal cords: functional significance and signaling mechanisms. J Pharmacol Exp Ther. 2013;347(3):765–772.
   PubMed Web of Science ®Google Scholar
• Huang CY, Chen YL, Li AH, et al. Minocycline, a microglial inhibitor, blocks spinal CCL2-induced heat hyperalgesia and augmentation of glutamatergic transmission in substantia gelatinosa neurons. J Neuroinflammation. 2014;11:7.
   PubMed Web of Science ®Google Scholar
• Zeilhofer HU. The glycinergic control of spinal pain processing. Cell Mol Life Sci CMLS. 2005;62(18):2027–2035.
   PubMed Web of Science ®Google Scholar
• Basbaum A, Bautista DM, Scherrer G, et al. Cellular and molecular mechanisms of pain. Cell. 2009;139(2):267–284.
   PubMed Web of Science ®Google Scholar
• Zeilhofer HU, Benke D, Yevenes G. Chronic pain states: pharmacological strategies to restore diminished inhibitory spinal pain control. Annu Rev Pharmacol Toxicol. 2012;52:111–133.
   PubMed Web of Science ®Google Scholar
• MacLeod BA, Wang JTC, Chung CCW, et al. Analgesic properties of the novel amino acid, isovaline. Anesth Analg. 2010;110(4):1206–1214.
   PubMed Web of Science ®Google Scholar
• Asseri KA, Puil E, Schwarz SK, et al. Group II metabotropic glutamate receptor antagonism prevents the antiallodynic effects of R-isovaline. Neuroscience. 2015;293:151–156.
   PubMed Web of Science ®Google Scholar
• Zhang J-Y, Gong N, Huang J-L, et al. Gelsemine, a principal alkaloid from Gelsemium sempervirens Ait., exhibits potent and specific anti-nociception in chronic pain by acting at spinal α3 glycine receptors. Pain. 2013;154(11):2452–2462.
   PubMed Web of Science ®Google Scholar
• Wu Y-E, Li Y-D, Luo Y-J, et al. Gelsemine alleviates both neuropathic pain and sleep disturbance in partial sciatic nerve ligation mice. Acta Pharmacol Sin. 2015;36(11):1308–1317.
   PubMed Web of Science ®Google Scholar
• Haranishi Y, Hara K, Terada T, et al. The anti-nociceptive effect of intrathecal administration of glycine transporter-2 inhibitor ALX1393 in a rat acute pain model. Anesth Analg. 2010;110(2):615–621.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Hara K, Haranishi Y, et al. Anti-nociceptive effect of intracerebroventricular administration of glycine transporter-2 inhibitor ALX1393 in rat models of inflammatory and neuropathic pain. Pharmacol Biochem Behav. 2015;130:46–52.
   PubMed Web of Science ®Google Scholar
• Edington AR, McKinzie AA, Reynolds AJ, et al. Extracellular loops 2 and 4 of GLYT2 are required for N-arachidonylglycine inhibition of glycine transport. J Biol Chem. 2009;284(52):36424–36430.
   PubMed Web of Science ®Google Scholar
• Morita K, Motoyama N, Kitayama T, et al. Spinal antiallodynia action of glycine transporter inhibitors in neuropathic pain models in mice. J Pharmacol Exp Ther. 2008;326(2):633–645.
   PubMed Web of Science ®Google Scholar
• Mingorance-Le Meur A, Ghisdal P, Mullier B, et al. Reversible inhibition of the glycine transporter GlyT2 circumvents acute toxicity while preserving efficacy in the treatment of pain. Br J Pharmacol. 2013;170(5):1053–1063.
   PubMed Web of Science ®Google Scholar
• Jiménez E, Zafra F, Perez-Sen R, et al. P2Y purinergic regulation of the glycine neurotransmitter transporters. J Biol Chem. 2011;286(12):10712–10724.
   PubMed Web of Science ®Google Scholar
• Andó RD, Méhész B, Gyires K, et al. A comparative analysis of the activity of ligands acting at P2X and P2Y receptor subtypes in models of neuropathic, acute and inflammatory pain. Br J Pharmacol. 2010;159(5):1106–1117.
   PubMed Web of Science ®Google Scholar
• Mobarakeh JI, Sakurada S, Katsuyama S, et al. Role of histamine H(1) receptor in pain perception: a study of the receptor gene knockout mice. Eur J Pharmacol. 2000;391(1–2):81–89.
   PubMed Web of Science ®Google Scholar
• Anoush M, Khani MRM. Evaluating the anti-nociceptive and anti-inflammatory effects of ketotifen and fexofenadine in rats. Adv Pharm Bull. 2014;5(2):217–222.
   Web of Science ®Google Scholar
• Cornbleet T. Use of intravenously given hydroxyzine for simple pain-producing office procedures. J Am Med Assoc. 1960;172(1):56–57.
   PubMed Web of Science ®Google Scholar
• Hupert C, Yacoub M, Turgeon LR. Effect of hydroxyzine on morphine analgesia for the treatment of postoperative pain. Anesth Analg. 1980;59(9):690–696.
   PubMed Web of Science ®Google Scholar
• Stambaugh JE, Lane C. Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination. Cancer Invest. 1983;1(2):111–118.
   PubMed Web of Science ®Google Scholar
• Duarte C, Dunaway F, Turner L, et al. Ketorolac versus meperidine and hydroxyzine in the treatment of acute migraine headache: a randomized, prospective, double-blind trial. Ann Emerg Med. 1992;21(9):1116–1121.
   PubMed Web of Science ®Google Scholar
• Erfanparast A, Tamaddonfard E, Taati M, et al. Role of the thalamic submedius nucleus histamine H1 and H2 and opioid receptors in modulation of formalin-induced orofacial pain in rats. Naunyn-Schmiedeberg’s Arch Pharmacol. 2015;388(10):1089–1096.
   Google Scholar
• Erfanparast A, Tamaddonfard E, Farshid AA, et al. Effect of microinjection of histamine into the dorsal hippocampus on the orofacial formalin-induced pain in rats. Eur J Pharmacol. 2010;627(1–3):119–123.
   PubMed Web of Science ®Google Scholar
• Tamaddonfard E, Rahimi S. Central effect of histamine and peripheral effect of histidine on the formalin-induced pain response in mice. Clin. Exp Pharmacol Physiol. 2004;31:518–522.
   PubMed Web of Science ®Google Scholar
• Mojtahedin A, Tamaddonfard E, Zanbouri A. Anti-nociception induced by central administration of histamine in the formalin test in rats. Indian J Physiol Pharmacol. 2008;52:249–254.
   PubMedGoogle Scholar
• Hamzeh-Gooshchi N, Tamaddonfard E, Farshid AA. Effects of microinjection of histamine into the anterior cingulate cortex on pain-related behaviors induced by formalin in rats. Pharmacol Rep. 2015;67(3):593–599.
   PubMed Web of Science ®Google Scholar
• Tamaddonfard E, Hamzeh-Gooshchi N. Effects of administration of histamine and its H1, H2, and H3 receptor antagonists into the primary somatosensory cortex on inflammatory pain in rats. Iran J Basic Med Sci. 2014;17(1):55.
   PubMed Web of Science ®Google Scholar
• Tamaddonfard E, Erfanparast A, Farshid AA, et al. Interaction between histamine and morphine at the level of the hippocampus in the formalininduced orofacial pain in rats. Pharmacol Rep. 2011;63(2):423–432.
   PubMed Web of Science ®Google Scholar
• Sanna MD, Stark H, Lucarini L, et al. Histamine H4 receptor activation alleviates neuropathic pain through differential regulation of ERK, JNK and P38 MAPK phosphorylation. Pain. 2015;156:2492–2504.
   PubMed Web of Science ®Google Scholar
• Kiss R, Keserű GM. Histamine H4 receptor ligands and their potential therapeutic applications: an update. Expert Opin Ther Pat. 2012;22(3):205–221.
   PubMed Web of Science ®Google Scholar
• Yue J-X, Wang -R-R, Yu J, et al. Histamine upregulates Nav1. 8 expression in primary afferent neurons via H2 receptors: involvement in neuropathic pain. CNS Neurosci Ther. 2014;20(10):883–892.
   PubMed Web of Science ®Google Scholar
• Yu J, Fang Q, Lou G-D, et al. Histamine modulation of acute nociception involves regulation of Nav1. 8 in primary afferent neurons in mice. CNS Neurosci Ther. 2013;19(9):649–658.
   PubMed Web of Science ®Google Scholar
• Wei H, Jin C-Y, Viisanen H, et al. Histamine in the locus coeruleus promotes descending noradrenergic inhibition of neuropathic hypersensitivity. Pharmacol Res. 2014;90:58–66.
   PubMed Web of Science ®Google Scholar
• Hui L, Yuan J, Ren Z, et al. Nerve growth factor reduces apoptotic cell death in rat facial motor neurons after facial nerve injury. Neurosciences. 2015;20(1):65–68.
   Web of Science ®Google Scholar
• Rukwied R, Mayer A, Kluschina O, et al. NGF induces non-inflammatory localized and lasting mechanical and thermal hypersensitivity in human skin. Pain. 2010;148:407–413.
   PubMed Web of Science ®Google Scholar
• Ettinger K, Nevo Y, Marcinkiewicz C, et al. Nerve growth factor-induced myoprotection in C2C12 muscle cells is mediated by α9β1 integrin via release of PGE2. J Basic Clin Physiol Pharmacol. 2015;26(4):411–415.
   PubMedGoogle Scholar
• Mizumura K, Taguchi T. Delayed onset muscle soreness: involvement of neurotrophic factors. J Phyiol Sci. 2016;66(1):42–52.
   Google Scholar
• Chen JW, Tong RX, Yang J, et al. Effects of Bushen Wenyang Huayu recipe on TRPV1 and sensitization factor NGF in experimental endometriosis. Zhonqquo Zhong Xi Yi Jie He Za Zhi. 2015;35(6):717–723.
   PubMedGoogle Scholar
• Luvone T, Affaitati G, De Filippis D, et al. Ultramicronized palmitoylethanolamide reduces viscero-visceral hyperalgesia in a rat model of endometriosis plus ureteral calculosis: role of mast cells. Pain. 2016;157(1):80–91.
   Web of Science ®Google Scholar
• López-Álvarez VM, Modol L, Navarro X, et al. Early increasing-intensity treadmill exercise reduces neuropathic pain by preventing nociceptor collateral sprouting and disruption of chloride cotransporters homeostasis after peripheral nerve injury. Pain. 2015;156(9):1812–1825.
   PubMed Web of Science ®Google Scholar
• Eskander MA, Ruparel S, Green DP, et al. Persistent nociception triggered by nerve growth factor (NGF) is mediated by TRPV1 and oxidative mechanisms. J Neurosci. 2015;35(22):8593–8603.
   PubMed Web of Science ®Google Scholar
• Isa ILM, Srivastava A, Tiernan D, et al. Hyaluronic acid based hydrogels attenuate inflammatory receptors and neurotrophins in interleukin-1β induced inflammation model of nucleus pulposus cells. Biomacromolecules. 2015;16(6):1714–1725.
   PubMed Web of Science ®Google Scholar
• Cirillo G, Cavaliere C, Bianco MR, et al. Intrathecal NGF administration reduces reactive astrocytosis and changes neurotrophin receptors expression pattern in a rat model of neuropathic pain. Cell Mol Neurobiol. 2010;30:51–62.
   PubMed Web of Science ®Google Scholar
• Kivitz AJ, Gimbel JS, Bramson C, et al. Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain. Pain. 2013;154(7):1009–1021.
   PubMed Web of Science ®Google Scholar
• Balanescu AR, Feist E, Wolfram G, et al. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial. Ann Rheum Dis. 2014;73(9):1665–1672.
   PubMed Web of Science ®Google Scholar
• Gow JM, Tsuji WH, Williams GJ, et al. Safety, tolerability, pharmacokinetics, and efficacy of AMG 403, a human anti-nerve growth factor monoclonal antibody, in two phase I studies with healthy volunteers and knee osteoarthritis subjects. Arthritis Res Ther. 2015 8;17:282.
   PubMed Web of Science ®Google Scholar
• Stoppiello L, Mapp P, Wilson D, et al. Structural associations of symptomatic knee osteoarthritis. Arthritis Rheumatol. 2014;66(11):3018–3027.
   PubMed Web of Science ®Google Scholar
• Seidel MF, Wise BL, Lane NE. Nerve growth factor: an update on the science and therapy. Osteoarthritis Cartilage. 2013;21(9):1223–1228.
   PubMed Web of Science ®Google Scholar
• Naveilhan P, Hassani H, Lucas G, et al. Reduced anti-nociception and plasma extravasation in mice lacking a neuropeptide Y receptor. Nature. 2001;409(1):513–517.
   PubMed Web of Science ®Google Scholar
• Shi T-JS, Li J, Dahlström A, et al. Deletion of the neuropeptide Y Y1 receptor affects pain sensitivity, neuropeptide transport and expression, and dorsal root ganglion neuron numbers. Neuroscience. 2006;140:293–304.
   PubMed Web of Science ®Google Scholar
• Wang L, Zhang L, Pan H, et al. Levels of neuropeptide Y in synovial fluid relate to pain in patients with knee osteoarthritis. BMC Musculoskeletal Disord. 2014;15:319.
   PubMed Web of Science ®Google Scholar
• Bokarewa M, Erlandsson M, Bjersing J, et al. Smoking is associated with reduced leptin and neuropeptide Y levels and higher pain experience in patients with fibromyalgia. Mediators Inflamm. 2014;2014:1–8. doi:10.1155/2014/627041.
   Web of Science ®Google Scholar
• Boateng EK, Novejarque A, Pheby T, et al. Heterogenous responses of dorsal root ganglion neurons in neuropathies induced by peripheral nerve trauma and the antiretroviral drug stavudine. Eur J Pain. 2015;19(2):236–245.
   PubMed Web of Science ®Google Scholar
• Sathyanesan M, Girgenti M, Warner-Schmidt J, et al. Indomethacin induced gene regulation in the rat hippocampus. Mol Brain. 2015;8:59.
   PubMed Web of Science ®Google Scholar
• Chun EH, Kim H, Suh CS, et al. Polymorphisms in neuropeptide genes and bone mineral density in Korean postmenopausal women. Menopause. 2015;22(11):1256–1263.
   PubMed Web of Science ®Google Scholar
• Carvajal C, Dumont Y, Herzog H, et al. Emotional behavior in aged neuropeptide Y (NPY) Y2 knockout mice. J Mol Neurosci. 2006;28:239–246.
   PubMed Web of Science ®Google Scholar
• Gautam M, Kumar R, Prasoon P, et al. Anti-nociceptive effect of 1400 W, an inhibitor of inducible nitric oxide synthase, following hind paw incision in rats. Nitric Oxide. 2015;50:98–104.
   PubMed Web of Science ®Google Scholar
• Khan S, Shehzad O, Cheng M-S, et al. Pharmacological mechanism underlying anti-inflammatory properties of two structurally divergent coumarins through the inhibition of pro-inflammatory enzymes and cytokines. J Inflamm (Lond). 2015;12:47.
   PubMed Web of Science ®Google Scholar
• Hervera A, Negrete R, Leánez S, et al. The role of nitric oxide in the local antiallodynic and antihyperalgesic effects and expression of delta-opioid and cannabinoid-2 receptors during neuropathic pain in mice. J Pharmacol Exp Ther. 2010;334(3):887–896.
   PubMed Web of Science ®Google Scholar
• Jin X-G, Chen S-R, Cao X-H, et al. Nitric oxide inhibits nociceptive transmission by differentially regulating glutamate and glycine release to spinal dorsal horn neurons. J Biol Chem. 2011;286:33190–33202.
   PubMed Web of Science ®Google Scholar
• Maire JJ, Close LN, Heinricher MM, et al. Distinct pathways for norepinephrine- and opioid-triggered anti-nociception from the amygdala. Eur J Pain. 2015. doi:10.1002/ejp.708.
   PubMed Web of Science ®Google Scholar
• Singh RB, Chopra N, Choubey S, et al. Role of Clonidine as adjuvant to intrathecal bupivacaine in patients undergoing lower abdominal surgery: a randomized control study. Anesth Essays Res. 2014;8(3):307–312.
   PubMedGoogle Scholar
• Sen J, Sen B. Response to low-dose intrathecal clonidine in septuagenarians undergoing sub-umbilical surgeries: a study. Saudi J Anaesth. 2015;9(2):142–147.
   PubMedGoogle Scholar
• Blaudszun G, Lysakowski C, Elia N, et al. Effect of perioperative systemic α2 agonists on postoperative morphine consumption and pain intensity: systematic review and meta-analysis of randomized controlled trials. Anesthesiology. 2012;116(6):1312–1322.
   PubMed Web of Science ®Google Scholar
• Surendar MN, Pandey RK, Saksena AK, et al. A comparative evaluation of intranasal dexmedetomidine, midazolam and ketamine for their sedative and analgesic properties: a triple blind randomized study. J Clin Pediatr Dentistry. 2014;38(3):255–261.
   PubMed Web of Science ®Google Scholar
• Soto N, Fauber AE, Ko JCH, et al. Analgesic effect of intra-articularly administered morphine, dexmedetomidine, or a morphine-dexmedetomidine combination immediately following stifle joint surgery in dogs. J Am Vet Med Assoc. 2014;244(11):1291–1297.
   PubMed Web of Science ®Google Scholar
• Gao Y, Guo X, Han P, et al. Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo. Int J Clin Pract. 2015;69:957–966. doi:10.1111/ijcp.12641.
   PubMed Web of Science ®Google Scholar
• Bhosale UA, Khobragade R, Naik C, et al. Randomized, double-blind, placebo-controlled study to investigate the pharmacodynamic interaction of 5-HT3 antagonist ondansetron and paracetamol in postoperative patients operated in an ENT department under local anesthesia. J Basic Clin Physiol Pharmacol. 2015;26(3):217–222.
   PubMedGoogle Scholar
• Pickering G, Estève V, Loriot M-A, et al. Acetaminophen reinforces descending inhibitory pain pathways. Clin Pharmacol Ther. 2008;84(1):47–51.
   PubMed Web of Science ®Google Scholar
• Pickering G, Loriot M-A, Libert F, et al. Analgesic effect of acetaminophen in humans: first evidence of a central serotonergic mechanism. Clin Pharmacol Ther. 2006;79(4):371–378.
   PubMed Web of Science ®Google Scholar
• Ren J, Ding X, Greer JJ. 5-HT1A receptor agonist Befiradol reduces fentanyl-induced respiratory depression, analgesia, and sedation in rats. Anesthesiology. 2015;122(2):424–434.
   PubMed Web of Science ®Google Scholar
• Kim JM, Jeong SW, Yang J, et al. Spinal 5-HT1A, not the 5-HT1B or 5-HT3 receptors, mediates descending serotonergic inhibition for late-phase mechanical allodynia of carrageenan-induced peripheral inflammation. Neurosci Lett. 2015 29;600:91–97.
   PubMed Web of Science ®Google Scholar
• Yesilyurt O, Seyrek M, Tasdemir S, et al. The critical role of spinal 5-HT7 receptors in opioid and non-opioid type stress-induced analgesia. Eur J Pharmacol. 2015;762:402–410. doi:10.1016/j.ejphar.2015.04.020.
   PubMed Web of Science ®Google Scholar
• Leombruni P, Miniotti M, Colonna F, et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clin Exp Rheumatol. 2015;33:S82–5.
   PubMed Web of Science ®Google Scholar
• Walitt B, Urrutia G, Nishishinya MB, et al. Selective serotonin reuptake inhibitors for fibromyalgia syndrome. Cochrane Database Syst Rev. 2015;5(8):CD011735.
   Google Scholar
• Regoli D, Boudon A, Fauchére JL. Receptors and antagonists for substance P and related peptides. Pharmacol Rev. 1994;46:551–599.
   PubMed Web of Science ®Google Scholar
• Rupniak NMJ, Webb JK, Williams AR, et al. Antinociceptive activity of the tachykinin NK1 receptor antagonist, CP-99,994, in conscious gerbils. Br J Pharmacol. 1995;116(2):1937–1943.
   PubMed Web of Science ®Google Scholar
• Gonzalez MI, Field MJ, Hughes J, et al. Evaluation of selective NK(1) receptor antagonist CI-1021 in animal models of inflammatory and neuropathic pain. J Pharmacol Exp Ther. 2000;294(2):444–450.
   PubMed Web of Science ®Google Scholar
• Cahill CM, Coderre TJ. Attenuation of hyperalgesia in a rat model of neuropathic pain after intrathecal pre- or post- treatment with a neurokinin-1 antagonist. Pain. 2002;95(3):277–285.
   PubMed Web of Science ®Google Scholar
• Dionne RA, Max MB, Gordon SM, et al. The substance P receptor antagonist CP-99,994 reduces acute postoperative pain. Clin Pharmacol Ther. 1998;64(5):562–568.
   PubMed Web of Science ®Google Scholar
• Chizh BA, Göhring M, Tröster A, et al. Effects of oral pregabalin and aprepitant on pain and central sensitization in the electrical hyperalgesia model in human volunteers. Br J Anaesth. 2007;98(2):246–254.
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Wang O, Gitter BD, et al. Dose-response study of the analgesic effect of lanepitant in patients with painful diabetic neuropathy. Clin Neuropharmacol. 2001;24(1):16–22.
   PubMed Web of Science ®Google Scholar
• Chen W, McRoberts JA, Marvizon JCV. µ-Opioid receptor inhibition of substance P release from primary afferents disappears in neuropathic pain but not inflammatory pain. Neuroscience. 2014;267:67–82.
   PubMed Web of Science ®Google Scholar
• Uematsu T, Sakai A, Ito H, et al. Intra-articular administration of tachykinin NK₁ receptor antagonists reduces hyperalgesia and cartilage destruction in the inflammatory joint in rats with adjuvant-induced arthritis. Eur J Pharmacol. 2011;668(1–2):163–168.
   PubMed Web of Science ®Google Scholar
• Liu NJ, Gintzler AR. Facilitative interactions between vasoactive intestinal polypeptide and receptor type-selective opioids: implications for sensory afferent regulation of spinal opioid action. Brain Res. 2003;959(1):103–110.
   PubMed Web of Science ®Google Scholar
• Tumati S, Largent-Milnes TM, Keresztes AI, et al. Tachykinin NK₁ receptor antagonist co-administration attenuates opioid withdrawal-mediated spinal microglia and astrocyte activation. Eur J Pharmacol. 2012;684(1–3):64–70.
   PubMed Web of Science ®Google Scholar
• Camargo LL, Denadai-Souza A, Yshii LM, et al. Peripheral neurokinin-1 receptors contribute to kaolin-induced acute monoarthritis in rats. Neuroimmunomodulation. 2015;22(6):373–384.
   PubMed Web of Science ®Google Scholar
• Chauhan VS, Kluttz JM, Bost KL, et al. Prophylactic and therapeutic targeting of the neurokinin-1 receptor limits neuroinflammation in a murine model of pneumococcal meningitis. J Immunol. 2011;186(12):7255–7263.
   PubMed Web of Science ®Google Scholar
• Simavli S, Thompson IR, Maguire CA, et al. Substance P regulates puberty onset and fertility in the female mouse. Endocrinology. 2015;156(6):2313–2322.
   PubMed Web of Science ®Google Scholar
• Niedermair T, Kuhn V, Doranehgard F, et al. Absence of substance P and the sympathetic nervous system impact on bone structure and chondrocyte differentiation in an adult model of endochondral ossification. Matrix Biol. 2014;38:22–35.
   PubMed Web of Science ®Google Scholar
• McDougall JJ, Watkins L, Li Z. Vasoactive intestinal peptide (VIP) is a modulator of joint pain in a rat model of osteoarthritis. Pain. 2006;123:98–105.
   PubMed Web of Science ®Google Scholar
• Schuelert N, McDougall JJ. Electrophysiological evidence that the vasoactive intestinal peptide receptor antagonist VIP 6–28 reduces nociception in an animal model of osteoarthritis. Osteoarthr Cartil. 2006;14(11):1155–1162.
   PubMed Web of Science ®Google Scholar
• Cernuda-Morollón E, Martínez-Camblor P, Alvarez R, et al. Increased VIP levels in peripheral blood outside migraine attacks as a potential biomarker of cranial parasympathetic activation in chronic migraine. Cephalalgia. 2015;35(4):310–316.
   PubMed Web of Science ®Google Scholar
• Amin FM, Hougaard A, Schytz HW, et al. Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38. Brain. 2014;137(Pt 3):779–794.
   PubMed Web of Science ®Google Scholar
• Shehab S, Al-Deen S. Fifth lumbar spinal nerve injury causes neurochemical changes in corresponding as well as adjacent spinal segments: a possible mechanism underlying neuropathic pain. J Chem Neuroanat. 2014;55:38–50.
   PubMed Web of Science ®Google Scholar
• Son S-J, Lee K-M, Jeon S-M, et al. Activation of transcription factor c-jun in dorsal root ganglia induces VIP and NPY upregulation and contributes to the pathogenesis of neuropathic pain. Exp Neurol. 2007;204(1):467–472.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Back SK, Kim J, et al. Increases in spinal vasoactive intestinal polypeptide and neuropeptide Y are not sufficient for the genesis of neuropathic pain in rats. Neurosci Lett. 2003;342(1–2):109–113.
   PubMed Web of Science ®Google Scholar
• Li J, Wang X, Liu H, et al. In silico classification and prediction of VIP derivatives as VPAC1/VPAC2 receptor agonists/antagonists. Comb Chem High Throughput Screen. 2015;18(1):33–41.
   PubMed Web of Science ®Google Scholar
• Smith MT, Muralidharan A. Targeting angiotensin II type 2 receptor pathways to treat neuropathic pain and inflammatory pain. Expert Opin Ther Targets. 2015;19(1):25–35.
   PubMed Web of Science ®Google Scholar
• Gris G, Portillo-Salido E, Aubel B, et al. The selective sigma-1 receptor antagonist E-52862 attenuates neuropathic pain of different aetiology in rats. Sci Rep. 2016;6:24591.
   PubMed Web of Science ®Google Scholar
• Chaparro LE, Smith SA, Moore RA, et al. Pharmacotherapy for the prevention of chronic pain after surgery in adults. Cochrane Database Syst Rev. 2013;24(7):CD008307.
   Google Scholar
• Clarke H, Bonin RP, Orser BA, et al. The prevention of chronic postsurgical pain using gabapentin and pregabalin: a combined systematic review and meta-analysis. Anesth Analg. 2012;115(2):428–442.
   PubMed Web of Science ®Google Scholar
• Kerfeld MJ, Hambsch ZJ, McEntire DM, et al. Physiologic advantages of peripheral nerve blockade translate to decreased length of stay and improved patient satisfaction. Open Anesthesiology. 2016;1:1.
   Google Scholar
• Fabi DW. Multimodal analgesia in the hip fracture patient. J Orthop Trauma. 2016;30:S6–S11.
   PubMedGoogle Scholar